Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

NCT00294372 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: BILR 355 BS
DRUG: Placebo

Sponsor

Boehringer Ingelheim